Alnylam Pharmaceuticals Inc $ 84.78 2.9 (3.54%)
Volume:
865,392
Avg Vol (1m):
678,262
Market Cap $:
9.43 Bil
Enterprise Value $:
7.84 Bil
P/E (TTM):
0.00
P/B:
5.24
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $84.78 | ||
Manual of Stocks™ Web
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 5.73 | ||
| Equity-to-Asset | 0.65 | ||
| Debt-to-Equity | 0.19 | ||
| Debt-to-EBITDA | -0.39 | ||
| Piotroski F-Score | 1 | ||
| Altman Z-Score | 3.99 | ||
| Beneish M-Score | 4.71 | ||
| WACC vs ROIC | |||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -890.09 | ||
| Net Margin % | -848.7 | ||
| ROE % | -55.69 | ||
| ROA % | -43.91 | ||
| ROC (Joel Greenblatt) % | -224.69 | ||
| 3-Year Revenue Growth Rate | 15.1 | ||
| 3-Year EBITDA Growth Rate | -34.6 | ||
| 3-Year EPS without NRI Growth Rate | -29.9 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 5.24 | ||
| PS Ratio | 88.59 | ||
| EV-to-EBIT | -8.71 | ||
| EV-to-EBITDA | -8.96 | ||
| EV-to-Revenue | 77.52 | ||
| Current Ratio | 6.28 | ||
| Quick Ratio | 6.16 | ||
| Days Inventory | 830.06 | ||
| Days Sales Outstanding | 110.97 | ||
| Days Payable | 2 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.24 | ||
| Price-to-Median-PS-Value | 1.13 | ||
| Earnings Yield (Greenblatt) % | -11.48 |